News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Pharmac To Consult On Glivec Access Criteria

PHARMAC is to begin consultation on access criteria for the chronic myeloid leukaemia (CML) drug Glivec (imatinib mesylate).

The move follows a recommendation from the Pharmacology and Therapeutics Advisory Committee (PTAC), and its Cancer Treatments Sub-committee (CaTSOP), who both recommended that PHARMAC examine funding Glivec for patients in the more advanced stages of CML, the accelerated and blast crisis phases.

PHARMAC and the suppliers of Glivec, Novartis, remain in discussions over the drug but have not yet reached an agreement.

PHARMAC chief executive Wayne McNee says: “PHARMAC has indicated its desire to fund this drug, but the key issue for us remains its extremely high price. We now want to hear the views of the community on this proposal before proceeding further.”

Consultation will take place over a four-week period, and PHARMAC will consider the feedback it receives before taking a further proposal to the PHARMAC Board.

Details of the consultation document will be finalised soon and distributed to clinicians, pharmacists and interested groups, and posted on the PHARMAC website ( PHARMAC estimates the proposal would encompass about 20 patients and cost between $75,000 and $105,000 per patient per year.

“While we are initially looking at criteria for the two most advanced stages of CML, access for patients in the chronic phase will continue to be reviewed.”

Wayne McNee says the available evidence shows Glivec to have significant benefits for patients with CML, but its long-term effects are not yet fully known and its high cost needs to be balanced against other competing demands on the pharmaceutical budget.

Novartis is supplying Glivec free to 30 patients on its extended access programme, and has agreed to continue supplying those patients for free until an agreement is reached with PHARMAC.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>